Difference between revisions of "Avatrombopag (Doptelet)"
Jump to navigation
Jump to search
m |
m (→Also known as) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
==Diseases for which it is established== | ==Diseases for which it is established== | ||
| − | *[[Immune thrombocytopenia | + | *[[Immune thrombocytopenia]] |
*[[Thrombocytopenia in liver disease]] | *[[Thrombocytopenia in liver disease]] | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 2018-05-21: Approved for [[Thrombocytopenia in liver disease|thrombocytopenia in adults with chronic liver disease]] scheduled to undergo a procedure. |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | * | + | *2019-06-20: Initial authorization as Doptelet |
| − | *Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. | + | *Uncertain date: Doptelet is indicated for the treatment of severe [[Thrombocytopenia in liver disease|thrombocytopenia in adult patients with chronic liver disease]] who are scheduled to undergo an invasive procedure. |
| − | *Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). | + | *Uncertain date: Doptelet is indicated for the treatment of primary chronic [[Immune thrombocytopenia|immune thrombocytopenia (ITP)]] in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). |
==Also known as== | ==Also known as== | ||
| − | *'''Code names:''' | + | *'''Code names:''' E-5501, YM-477, AKR-501 |
*'''Brand name:''' Doptelet | *'''Brand name:''' Doptelet | ||
Latest revision as of 13:11, 8 September 2023
Mechanism of action
Thrombopoietin receptor agonist
Diseases for which it is established
History of changes in FDA indication
- 2018-05-21: Approved for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
History of changes in EMA indication
- 2019-06-20: Initial authorization as Doptelet
- Uncertain date: Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.
- Uncertain date: Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).
Also known as
- Code names: E-5501, YM-477, AKR-501
- Brand name: Doptelet